---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018884"
form_type: "8-K"
ticker: "AIMD"
cik: "0001014763"
company_name: "Ainos, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T01:44:19.228198+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ainos Q1 revenue down 58% YoY to $20.7K; net loss widens to $3.3M; secures $9M convertible note

## Summary
- Revenue of $20,729 in Q1 2024, down 58% from $49,164 in Q1 2023, due to pivot from COVID-19 test kits.
- Net loss attributable to common stockholders was $3.3M, compared to $2.5M in prior year.
- Cash and cash equivalents $1.03M as of Mar 31, 2024, down from $1.89M at Dec 31, 2023.
- Raised $9M convertible note post-quarter (6% interest, convertible at $4.50/sh) from existing shareholder.
- Submitted clinical hold response to FDA for VELDONA Phase II trial for mild COVID-19.

## SEC filing metadata
- accession: 0001493152-24-018884
- form_type: 8-K
- ticker: AIMD
- cik: 0001014763
- company_name: Ainos, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014763/000149315224018884/0001493152-24-018884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014763/000149315224018884/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018884
- JSON: https://secwatch.observer/filing/0001493152-24-018884.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018884.txt

## Key facts
- Earnings Releases
  Ainos, Inc. reported first quarter ended March 31, 2024 results: revenue US$20,729, net income US$3,314,810.
  - Period: first quarter ended March 31, 2024
  - Revenue: US$20,729
  - Net income: US$3,314,810
  - Result: reported results
  source text: Revenues were US$20,729 in the first quarter of 2024, compared to US$49,164 in the same period of 2023, reflecting the Company’s cessation of sales of its COVID-19 antigen rapid test kits during the first quarter of 2024 after a strategic pivot shift.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1014763/000149315224018884/0001493152-24-018884-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.